Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Phase 2
Completed
- Conditions
- Alcoholism
- Registration Number
- NCT00147576
- Lead Sponsor
- Pfizer
- Brief Summary
Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
- Subject meets the DSM-IV criterion for current alcohol dependence.
- Subject is currently not engaged in, and does not want, treatment for alcohol related problems.
Exclusion Criteria
- Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine.
- Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The amount of alcohol consumed will be based on the total number of standardized drinks consumed during a two-hour laboratory-based self-administration procedure following 7 days of treatment with study medication.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸San Antonio, Texas, United States
Pfizer Investigational Site🇺🇸San Antonio, Texas, United States